Life Science Investing Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301
Life Science Investing Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors
Life Science Investing Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy
Life Science Investing Benitec Biopharma Releases Full Year 2025 Financial Results and Provides Operational Update
Alvopetro Announces Q3 2025 Financial Results and an Operational Update Including Record October Sales
Allied Critical Metals Expands Santa Helena Breccia with 6.0 Metres of 1.02% WO3 Intercept at Borralha
